

## PRODUCT MONOGRAPH

### **HepaGam B<sup>®</sup>**

Hepatitis B Immune Globulin (Human) Injection

Liquid >312 IU/mL

Standard: World Health Organization (WHO) International Reference Preparation

Passive Immunizing Agent

**HepaGam B<sup>®</sup>, indicated for the prevention of hepatitis B recurrence following liver transplantation, has been issued marketing authorization with conditions pending the results of studies to verify its clinical benefit. Patients should be advised of the nature of the authorization.**

Saol Therapeutics Research Limited

Dublin, Ireland

Distributor (in Canada): Emergent BioSolutions  
Canada Inc.,

a subsidiary of Emergent BioSolutions Inc.

Control No.: 211495

Date of Approval: December 20, 2017

**This product has been approved under the Notice of Compliance with Conditions (NOC/c) policy for one of its indicated uses.**

### **What is a Notice of Compliance with Conditions (NOC/c)?**

An NOC/c is a form of market approval granted to a product on the basis of promising evidence of clinical effectiveness following review of the submission by Health Canada.

Products approved under Health Canada's NOC/c policy are intended for the treatment, prevention or diagnosis of a serious, life-threatening or severely debilitating illness. They have demonstrated promising benefit, are of high quality and possess an acceptable safety profile based on a benefit/risk assessment. In addition, they either respond to a serious unmet medical need in Canada or have demonstrated a significant improvement in the benefit/risk profile over existing therapies. Health Canada has provided access to this product on the condition that sponsors carry out additional clinical trials to verify the anticipated benefit within an agreed upon time frame.

### **What will be different about this Product Monograph?**

The following Product Monograph will contain boxed text at the beginning of each major section clearly stating the nature of the market authorization. Sections for which NOC/c status holds particular significance will be identified in the left margin by the symbol **NOC/c**. These sections may include, but are not limited to, the following:

- Indications and Clinical Uses
- Action
- Warnings and Precautions
- Adverse Reactions
- Dosage and Administration and
- Clinical Trials

### **Adverse Drug Reaction Reporting and Re-Issuance of the Product Monograph**

Health care providers are encouraged to report Adverse Drug Reactions associated with normal use of these and all drug products to Health Canada's Health Product Safety Information Division at 1-866-234-2345. The Product Monograph will be re-issued in the event of serious safety concerns previously unidentified or at such time as the sponsor provides the additional data in support of the product's clinical benefit. Once the latter has occurred, and in accordance with the NOC/c policy, the conditions associated with market authorization will be removed.

## TABLE OF CONTENTS

<b>PART I: HEALTH PROFESSIONAL INFORMATION.....</b>	<b>4</b>
<b>SUMMARY PRODUCT INFORMATION.....</b>	<b>4</b>
<b>DESCRIPTION.....</b>	<b>4</b>
<b>INDICATIONS AND CLINICAL USE.....</b>	<b>5</b>
<b>CONTRAINDICATIONS.....</b>	<b>6</b>
<b>WARNINGS AND PRECAUTIONS.....</b>	<b>6</b>
<b>ADVERSE REACTIONS.....</b>	<b>9</b>
<b>DRUG INTERACTIONS.....</b>	<b>12</b>
<b>DOSAGE AND ADMINISTRATION.....</b>	<b>13</b>
<b>OVERDOSAGE.....</b>	<b>17</b>
<b>ACTION AND CLINICAL PHARMACOLOGY.....</b>	<b>17</b>
<b>STORAGE AND STABILITY.....</b>	<b>19</b>
<b>SPECIAL HANDLING INSTRUCTIONS.....</b>	<b>19</b>
<b>DOSAGE FORMS, COMPOSITION AND PACKAGING.....</b>	<b>19</b>
<b>PART II: SCIENTIFIC INFORMATION.....</b>	<b>21</b>
<b>PHARMACEUTICAL INFORMATION.....</b>	<b>21</b>
<b>CLINICAL TRIALS.....</b>	<b>23</b>
<b>DETAILED PHARMACOLOGY.....</b>	<b>28</b>
<b>TOXICOLOGY.....</b>	<b>29</b>
<b>REFERENCES.....</b>	<b>29</b>
<b>PART III: CONSUMER INFORMATION.....</b>	<b>32</b>

# HEPAGAM B®

Hepatitis B Immune Globulin (Human) Injection

## PART I: HEALTH PROFESSIONAL INFORMATION

HepaGam B, indicated for the prevention of hepatitis B recurrence following liver transplantation, has been issued marketing authorization with conditions pending the results of studies to verify its clinical benefit. Patients should be advised of the nature of the authorization.

### SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Clinically Relevant Nonmedicinal Ingredients
<b>Intramuscular</b> for the post-exposure prophylaxis indication <b>Intravenous</b> for the liver transplantation indication	Liquid >312 IU/mL Hepatitis B Immune Globulin (Human)	For a complete listing see <b>DOSAGE FORMS, COMPOSITION AND PACKAGING</b> section

### DESCRIPTION

HepaGam B (Hepatitis B Immune Globulin (Human) Injection), is a sterile solution of purified gamma globulin (IgG) fraction of human plasma containing antibodies to hepatitis B surface antigen (anti-HBs). HepaGam B is manufactured from plasma collected from healthy, screened donors with high titres of anti-HBs which is purified by an anion-exchange column chromatography method (1, 2).

HepaGam B is prepared from pools of human plasma which may contain the causative agents of hepatitis and other viral diseases. The manufacturing process includes both a Planova® 20 nm virus filter that effectively removes lipid-enveloped and non-enveloped viruses based on size, and a solvent/detergent treatment step (using tri-n-butyl phosphate and Triton X-100®) that effectively inactivates lipid-enveloped viruses (3, 4, 5). These two processes are designed to increase product safety by reducing the risk of viral transmission of several viruses including human immunodeficiency virus (HIV), hepatitis B (HBV) and hepatitis C (HCV). However, despite these measures, such products can still potentially transmit disease. There is also the possibility that unknown infectious agents may be present in such products (see **WARNINGS AND PRECAUTIONS**).

The product potency is expressed in international units (IU) by comparison to the World Health Organization (WHO) international Hepatitis B Immune Globulin reference preparation. Each vial contains greater than 312 IU/mL of anti-HBs.

HepaGam B is stabilized with 10% maltose and 0.03% polysorbate 80. The product contains no preservative.

## **INDICATIONS AND CLINICAL USE**

### **Post-exposure Prophylaxis**

HepaGam B is indicated for the treatment of acute exposure to blood containing hepatitis B surface antigen (HBsAg), perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute HBV infection in the following settings:

#### **Acute Exposure to Blood Containing HBsAg**

Following either parenteral exposure (needlestick, bite, sharps), direct mucous membrane contact (accidental splash), or oral ingestion (pipetting accident) involving HBsAg-positive materials such as blood, plasma, or serum (6, 7).

#### **Perinatal Exposure of Infants Born to HBsAg-positive Mothers**

Infants born to mothers positive for HBsAg with or without Hepatitis B e antigen (HBeAg) (6).

#### **Sexual Exposure to HBsAg-positive Persons**

Sexual partners of HBsAg-positive persons (6, 7).

#### **Household Exposure to Persons with Acute HBV Infection**

Infants less than 12 months old whose mother or primary caregiver is positive for HBsAg, or other household contacts with identifiable blood exposure to the index patient.

HepaGam B is administered intramuscularly for post-exposure prophylaxis.

### **Prevention of Hepatitis B Recurrence Following Liver Transplantation**

HepaGam B is indicated for the prevention of hepatitis B recurrence following liver transplantation in adult patients with hepatitis B who have no or low levels of HBV replication (8, 9). The efficacy of HepaGam B in conjunction with antivirals such as lamivudine will be assessed in a Phase III confirmatory study. HepaGam B should be administered intravenously for this indication. For more information, see **PART II: SCIENTIFIC INFORMATION, CLINICAL TRIALS**.

**Geriatrics (>65 years of age):** No data is available.

**Pediatrics (<18 years of age):** HepaGam B was found to be safe and effective in a pediatric population (infants born to mothers who were HBsAg-positive). The protection rate against

**NOC/c**

development of hepatitis B in infants, born to mothers who were HBsAg-positive, was 98%. No safety concerns were identified.

## CONTRAINDICATIONS

For post-exposure prophylaxis indications, HepaGam B is administered intramuscularly. In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, HepaGam B should be given only if the expected benefits outweigh the potential risks.

### NOC/c

Patients with a history of anaphylactic or severe system reaction to any component of the product.

Patients who are deficient in IgA. While HepaGam B contains less than 40 µg/mL IgA, individuals who are deficient in IgA may have the potential to develop IgA antibodies and have an anaphylactoid reaction.

## WARNINGS AND PRECAUTIONS

### Serious Warnings and Precautions

HepaGam B is prepared from pools of human plasma which may contain the causative agents of hepatitis and other viral diseases. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by inactivating and/or removing certain viruses during manufacturing. Despite these measures, such products can still potentially transmit disease. There is also the possibility that unknown infectious agents may be present in such products.

True hypersensitivity reactions are rare. These reactions can occur in very rare cases of IgA deficiency or hypersensitivity to human globulin. In case of allergic or anaphylactic reaction, the infusion should be stopped immediately. In case of shock, the current medical standards for treatment of shock should be observed.

The physician should discuss the risks and benefits of this product with the patient before prescribing or administering to the patient (see **WARNINGS AND PRECAUTIONS, General**).

### General

Although HepaGam B is formulated for intravenous or intramuscular administration, HepaGam B should only be administered intravenously for the prevention of hepatitis B recurrence following liver transplantation. Intravenous administration is required due to the large volume required per dose (35 mL) and because many liver transplant patients will have thrombocytopenia or coagulation disorders following transplantation, which may contraindicate intramuscular administration.

### NOC/c

For intravenous administration, following liver transplant, certain adverse drug reactions may be related to the rate of infusion. The recommended infusion rate given under **DOSAGE AND**

**ADMINISTRATION, Administration** must be closely followed. Patients must be closely monitored and carefully observed for any symptoms throughout the infusion period and immediately following an infusion.

If patients develop treatment-related adverse events due to immune complex formation between HBIG and circulating HBsAg, dose adjustments may be required. Symptoms related to immune complexes should be treated with antihistamines or analgesic agents and the HepaGam B infusion rate should be decreased (see **Administration**).

HepaGam B is made from human plasma. Products made from human plasma may contain infectious agents such as viruses and, theoretically, the Creutzfeldt-Jakob disease agent. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by inactivating and/or removing certain viruses. The manufacturing process includes both a Planova<sup>®</sup> 20 nm virus filter that effectively removes lipid-enveloped and non-enveloped viruses based on size, and a solvent/detergent treatment step (using tri-n-butyl phosphate and Triton X-100<sup>®</sup>) that effectively inactivates lipid-enveloped viruses by irreversibly destroying the lipid coat (3, 4, 5). These two processes are designed to increase product safety by reducing the risk of viral transmission of several viruses including human immunodeficiency virus (HIV), hepatitis B and hepatitis C. However, despite these measures, such products can still potentially transmit disease. There is also the possibility that unknown infectious agents may be present in such products. Individuals who receive infusions of blood or plasma products may develop signs and/or symptoms of some viral infections. All infections thought to have been possibly transmitted by this product should be reported by the physician or other health care provider to Saol Therapeutics Research Limited at 1-877-443-0224.

### **Cardiovascular**

For the post-exposure prophylaxis indications, HepaGam B is administered intramuscularly. In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, HepaGam B should be given only if the expected benefits outweigh the potential risks.

Rare thrombotic events have been reported in association with immune globulin intravenous (Human) (IGIV) (10, 11, 12). Patients at risk may include those with a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, hypercoagulable disorders, prolonged periods of immobilization, and/or known or suspected hyperviscosity. Although the risk of thrombotic adverse events following HepaGam B is extremely low, care should be taken in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies (see **WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests**). For patients who are at risk of developing thrombotic events, administer HepaGam B at the minimum rate of infusion practicable.

### **Renal**

Intravenous immune globulin (human) products have been reported to produce renal dysfunction in patients that are predisposed to acute renal failure or those that have renal insufficiency. In

such patients, it has been recommended that intravenous immune globulin (human) products be administered at a minimum practical concentration and infusion rate. While renal dysfunction has been reported with various intravenous immune globulin (human) products (13, 14, 15), the vast majority of these reports have involved products that utilize sucrose as a stabilizer.

**HepaGam B does not contain sucrose as a stabilizer.** Regardless, it is recommended that renal function be assessed prior to administration of HepaGam B and at appropriate intervals following administration, especially for patients at risk of developing acute renal failure. If renal dysfunction occurs, clinical judgment should be used to determine whether the infusion rate of HepaGam B should be decreased or the product should be discontinued.

### **Sensitivity**

Although allergic reactions have not been reported following HepaGam B administration (see **Adverse Drug Reaction Overview**), epinephrine and diphenhydramine should be available for the treatment of any allergic reactions.

HepaGam B contains trace amounts of IgA (<40 µg/mL). Patients with known antibodies to IgA may have a greater risk of severe hypersensitivity and anaphylactic reactions. HepaGam B is contraindicated in IgA deficient patients with antibodies against IgA and a history of hypersensitivity reactions (see **CONTRAINDICATIONS**).

### **Special Populations**

#### **Pregnant Women:**

Animal reproduction studies have not been conducted with HepaGam B. It is also not known whether HepaGam B can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. However, immune globulins have been widely used during pregnancy for many years without any apparent negative reproductive effects (16). The risk/benefit of HepaGam B administration should be assessed for each individual case.

Extent of exposure in pregnancy during clinical trials: No experience.

#### **Nursing Women:**

It is not known whether HepaGam B is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when HepaGam B is administered to a nursing mother.

#### **Pediatrics (<18 years of age):**

HepaGam B was found to be safe and effective for prevention of vertical transmission of the hepatitis B virus. Infants born to mothers who were HBsAg-positive had a protection rate against developing the hepatitis B virus of 98%. No safety concerns were identified during the trial.

#### **Geriatrics (>65 years of age):**

Safety and effectiveness in the geriatric population have not been established for HepaGam B.



## **Monitoring and Laboratory Tests**

Liver transplant patients should be monitored regularly for serum anti-HBs antibody levels.

### **Assessment and Monitoring for Thrombotic Risk Factors**

Because of the potentially increased risk of thrombosis, baseline assessment of blood viscosity should be considered in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies.

### **Blood Glucose Testing**

The maltose contained in HepaGam B can interfere with some types of blood glucose monitoring systems, i.e., those based on the glucose dehydrogenase pyrroloquinone (GDH-PQQ) method. This can result in falsely elevated glucose readings and, consequently, in the inappropriate administration of insulin resulting in life-threatening hypoglycemia. Cases of true hypoglycemia may go untreated if the hypoglycemic state is masked by falsely elevated results.

## **ADVERSE REACTIONS**

### **Adverse Drug Reaction Overview**

#### **Post-exposure Prophylaxis**

In clinical trial HB-004, 253 infants born to HBsAg-positive mothers received a single dose of HepaGam B and hepatitis B vaccine intramuscularly within 12 hours of birth. A total of 531 adverse events were reported for 159 of the infants (63%). The most common adverse events were diarrhea (57 events) and pyrexia (52 events). The majority of adverse events were mild in intensity. Only one adverse event, indurations of the right and left thighs, was reported as possibly treatment-related. A total of 43 serious adverse event terms were captured on Case Report Forms (CRFs) for 38 infants during the study. None of the serious adverse events were related to HepaGam B administration.

In addition, 42 adult males and females were administered a single dose of HepaGam B along with hepatitis B vaccine within 48 hours of possible exposure to hepatitis B virus (needle stick, bite, sharps, etc). A total of 69 adverse events were reported for 25 of the patients (60%). The most frequent adverse event was headache (12 events). The majority of events were reported as mild. Nineteen adverse events were reported as possibly related to HepaGam B administration. The most common related adverse events were nausea, pyrexia, arthralgia, myalgia and headache.

## **NOC/c**

### **Prevention of Hepatitis B Recurrence Following Liver Transplantation**

The most common expected adverse drug reactions for intravenous immune globulins like HepaGam B are chills, fever, headaches, vomiting, allergic reactions, nausea, arthralgia and moderate low back pain (8, 9, 17). In a clinical trial in liver transplant patients, two adverse drug reactions of tremor and hypotension were reported in two of 14 patients who received intravenous infusions of HepaGam B (18). In studies with healthy volunteers, only one adverse

drug reaction of nausea had been reported in the 70 adult subjects who received an intramuscular administration of HepaGam B (18).

Although no anaphylactic reactions have been reported following HepaGam B administration, anaphylactic reactions have been reported following the administration of intravenous immune globulin (human) products on rare occasions (see **WARNINGS AND PRECAUTIONS, General**) (19).

### **Clinical Trial Adverse Drug Reactions**

Because clinical trials are conducted under very specific conditions, the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

### **Hepatitis B-Related Liver Transplantation**

In an ongoing clinical trial, only two adverse drug reactions occurred following the 313 (<1%) HepaGam B infusions in 14 liver transplant patients. These adverse events were reported in an interim analysis from a Phase III clinical trial examining HepaGam B for the prevention of hepatitis B recurrence following liver transplantation. This study utilized the recommended dosing regimen outlined in Table 4 (see **DOSAGE AND ADMINISTRATION**). The two adverse drug reactions of tremor and hypotension were reported in two patients. All reactions were associated with a single HepaGam B infusion during the first week post-transplant. All reactions resolved on the same day and did not recur with subsequent HepaGam B infusions.

### **Healthy Volunteer Studies**

Seventy healthy male and female volunteers received a single dose of HepaGam B, Hepatitis B Immune Globulin (Human), intramuscularly in clinical trials (18). Seventeen subjects reported 30 adverse events following administration of HepaGam B. The most frequently reported adverse events included four subjects (6%) who experienced headache, seven subjects (10%) who had cold symptoms or flu and two subjects (3%) who experienced lightheadedness/fainted. The majority of events were reported as mild. One adverse event, an episode of nausea, was considered to be drug related. There were no serious adverse events reported. A similar number of subjects in the comparator groups reported adverse events.

### **Abnormal Hematologic and Clinical Chemistry Findings**

There have been no abnormal hematology or clinical chemistry values reported to be related to HepaGam B administration.

### **Post-market Adverse Drug Reactions**

The following adverse reactions have been identified during post-approval use of HepaGam B. Because these reactions are reported voluntarily from a population of uncertain size, it is not

always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

The system organ classification of reported adverse reactions is provided below:

<b>Cardiac Disorders:</b>	Sinus tachycardia
<b>Gastrointestinal Disorders:</b>	Abdominal pain
	Nausea
<b>General Disorders and Administration Site Conditions:</b>	Asthenia
	Chest pain
	Chills
	Feeling cold
	Feeling hot
	Influenza like illness
	Malaise
	Pain
	Pyrexia
<b>Immune System Disorders:</b>	Anaphylactoid reaction
	Anaphylactic shock
	Hypersensitivity
<b>Investigations:</b>	Lipase increased
	Transaminases increased
<b>Musculoskeletal and Connective Tissue Disorders:</b>	Back pain
	Groin pain
<b>Nervous System Disorders:</b>	Dizziness
	Headache
<b>Respiratory, Thoracic and Mediastinal Disorders:</b>	Dyspnoea
<b>Skin and Subcutaneous Tissue Disorders:</b>	Cold sweat
	Rash erythematous
<b>Vascular Disorders:</b>	Flushing

## DRUG INTERACTIONS

### Serious Drug Interactions

Live attenuated virus vaccines: immune globulin administration may impair the efficacy of live attenuated virus vaccines for a period of three months or more (see **DRUG INTERACTIONS, Overview**).

### Overview

Immune globulin administration may impair the efficacy of live attenuated virus vaccines such as measles, rubella, mumps and varicella (17, 20, 21). Vaccination with live virus vaccines should be deferred until approximately three months after administration of HepaGam B (Hepatitis B Immune Globulin (Human) Injection). Persons who received HepaGam B less than 14 days after live virus vaccination should be revaccinated three months after the administration of the immune globulin, unless serologic test results indicate that antibodies were produced (22).

There are no available data on concomitant use of HepaGam B and other medications.

Antibodies present in HepaGam B may interfere with some serological tests (see **Drug-Laboratory Interactions**).

### Drug-Drug Interactions

**Table 1 Established or Potential Drug-Drug Interactions**

Hepatitis B Immune Globulin (Human)	Reference	Effect	Clinical Comment
Live attenuated virus vaccines (e.g. measles, rubella, mumps, varicella)	T	Immune globulin may impair efficacy	If Hepatitis B Immune Globulin is given less than 14 days after live virus vaccination, revaccination should be considered.

T = Theoretical

The use of live virus vaccination before or after HepaGam B administration should follow the recommendations by the Canadian National Advisory Committee on Immunization (22).

Interactions with other drugs have not been established.

### Drug-Food Interactions

Interactions with food have not been established.

### Drug-Herb Interactions

Interactions with herbal products have not been established.

## **Drug-Laboratory Interactions**

After administration of Hepatitis B Immune Globulin (Human), a transitory increase of passively transferred antibodies in the patient's blood may result in misleading positive results in serological testing (e.g. 'Coombs' test).

HepaGam B contains maltose, which can interfere with certain types of blood glucose testing and monitoring systems, i.e., those based on the GDH-PQQ (see **WARNINGS AND PRECAUTIONS, Blood Glucose Testing**). Even though HepaGam B is administered intravenously, due to the potential for falsely elevated glucose readings only testing systems that are glucose-specific should be used to test or monitor blood glucose levels in patients receiving maltose-containing parenteral products, including HepaGam B.

The product information of the blood glucose testing system, including that of the test strips, should be carefully reviewed to determine if the system is appropriate for use with maltose-containing parenteral products. If any uncertainty exists, contact the manufacturer of the testing system to determine if the system is appropriate for use with maltose-containing parenteral products.

## **DOSAGE AND ADMINISTRATION**

### **Dosing Considerations**

#### **Post-exposure Prophylaxis**

For post-exposure prophylaxis indications, HepaGam B is administered intramuscularly as directed below.

It is important to use a separate vial, sterile syringe, and needle for each individual patient to prevent transmission of infectious agents from one person to another.

HepaGam B may be administered at the same time (but at different site), or up to one month preceding hepatitis B vaccination without impairing the active immune response to hepatitis B vaccine (6, 7). Efficacy of live attenuated virus vaccines may be impaired by immune globulin administration; revaccination may be necessary.

#### **Acute Exposure to Blood Containing HBsAg**

Table 2 below summarizes prophylaxis for percutaneous (needlestick, bite, sharps), ocular, or mucous membrane exposure to blood according to the source of exposure and vaccination status of the exposed person. For greatest effectiveness, passive prophylaxis with HepaGam B should be given as soon as possible after exposure, as its value after seven days following exposure is unclear (6, 7). An injection of 0.06 mL/kg of body weight should be administered intramuscularly as soon as possible after exposure and within 24 hours if possible. Consult the hepatitis B vaccine package insert for dosage information regarding the vaccine.

For persons who refuse hepatitis B vaccine or who are known non-responders to vaccine, a second dose of HepaGam B should be given one month after the first dose.

**Table 2 Recommendations for Hepatitis B Prophylaxis following Percutaneous or Permucosal Exposure**

Source	Exposed Person	
	Unvaccinated	Vaccinated
HBsAg-positive	1. Hepatitis B Immune Globulin (Human) x 1 immediately <sup>a</sup> 2. Initiate HB vaccine series <sup>b</sup>	1. Test exposed person for anti-HBs 2. If inadequate antibody <sup>c</sup> , Hepatitis B Immune Globulin (Human) x 1 immediately plus either HB vaccine booster dose, or a second dose of Hepatitis B Immune Globulin (Human) <sup>a</sup> , 1 month later.
Known Source – High Risk for HBsAg-positive	1. Initiate HB vaccine series 2. Test source of HBsAg. If positive, Hepatitis B Immune Globulin (Human) x 1	1. Test source for HBsAg only if exposed is vaccine nonresponder; if source is HBsAg-positive, give Hepatitis B Immune Globulin (Human) x 1 immediately plus either HB vaccine booster dose, or a second dose of Hepatitis B Immune Globulin (Human)*, 1 month later <sup>d</sup>
Known Source – Low Risk for HBsAg-positive	Initiate HB vaccine series	Nothing required
Unknown Source	Initiate HB vaccine series	Nothing required

<sup>a</sup> Hepatitis B Immune Globulin (Human) dose of 0.06 mL/kg (intramuscular)

<sup>b</sup> See manufacturer's recommendation for appropriate dose.

<sup>c</sup> Less than 10 mIU/mL anti-HBs by radioimmunoassay, negative by enzyme immunoassay.

<sup>d</sup> Two doses of Hepatitis B Immune Globulin (Human) is preferred if no response after at least four doses of vaccine.

*Prophylaxis of Infants Born to Mothers who are Positive for HBsAg with or without HBeAg*

Table 3 contains the recommended schedule of hepatitis B prophylaxis for infants born to mothers that are either known to be positive for HBsAg or have not been screened. Infants born to mothers known to be HBsAg-positive should receive 0.5 mL HepaGam B after physiologic stabilization of the infant and preferably within 12 hours of birth. The hepatitis B vaccine series should be initiated simultaneously, if not contraindicated, with the first dose of the vaccine given concurrently with the HepaGam B, but at a different site. Subsequent doses of the vaccine should be administered in accordance with the recommendations of the manufacturer. Women admitted for delivery, who were not screened for HBsAg during the prenatal period, should be tested. While test results are pending, the newborn infant should receive hepatitis B vaccine within 12 hours of birth (see manufacturer's recommendations for dose). If the mother is later found to be HBsAg-positive, the infant should receive 0.5 mL HepaGam B as soon as possible and within seven days of birth; however, the efficacy of HepaGam B administered after 48 hours of age is not known (23). Testing for HBsAg and anti-HBs is recommended at 12 to 15 months of age. If HBsAg is not detectable and anti-HBs is present, the child has been protected (6).

**Table 3 Recommended Schedule of Hepatitis B Immunoprophylaxis to Prevent Perinatal Transmission of Hepatitis B Virus Infection (6)**

<b>Age of Infant</b>		
<b>Administer</b>	<b>Infant Born to Mother Known to be HBsAg-positive</b>	<b>Infant Born to Mother Not Screened for HBsAg</b>
First Vaccination <sup>a</sup> Hepatitis B Immune Globulin (Human) <sup>b</sup>	Birth (within 12 hours) Birth (within 12 hours)	Birth (within 12 hours) If mother is found to be HBsAg-positive, administer dose to infant as soon as possible, not later than 1 week after birth
Second Vaccination <sup>a</sup>	1 month	1–2 months
Third Vaccination <sup>a</sup>	6 months <sup>c</sup>	6 months <sup>c</sup>

<sup>a</sup> See manufacturer’s recommendation for appropriate dose

<sup>b</sup> 0.5 mL administered intramuscularly at a site different from that used for the vaccine

<sup>c</sup> See ACIP recommendation (6)

*Sexual Exposure to HBsAg-positive Persons*

All susceptible persons whose sexual partners have acute hepatitis B infection should receive a single dose of HepaGam B (0.06 mL/kg) and should begin the hepatitis B vaccine series, if not contraindicated, within 14 days of the last sexual contact or if sexual contact with the infected person will continue. Administering the vaccine with HepaGam B may improve the efficacy of post-exposure treatment. The vaccine has the added advantage of conferring long-lasting protection (6, 7).

*Household Exposure to Persons with Acute HBV Infection*

Prophylaxis of an infant less than 12 months of age with 0.5 mL HepaGam B and hepatitis B vaccine is indicated if the mother or primary caregiver has acute HBV infection. Prophylaxis of other household contacts of persons with acute HBV infection is not indicated unless they had an identifiable blood exposure to the index patient, such as by sharing toothbrushes or razors. Such exposures should be treated like sexual exposures. If the index patient becomes an HBV carrier, all household contacts should receive hepatitis B vaccine (6, 7).

*Administration*

HepaGam B should be prepared for intramuscular administration under aseptic conditions. **DO NOT SHAKE VIAL; AVOID FOAMING.** Parenteral drugs should be visually assessed for particulate matter and discoloration prior to administration. HepaGam B should be administered intramuscularly within 12 hours of birth in infants, or within 48 hours of exposure for adults. Injection should be given into the deltoid muscle or into the anteriolateral thigh in term infants. If administered in combination with hepatitis B vaccine, HepaGam B must be injected into a separate site to prevent vaccine neutralization.

**NOC/c**

*Prevention of Hepatitis B Recurrence Following Liver Transplantation*

For the prevention of hepatitis B recurrence following liver transplantation in adult patients with hepatitis B, HepaGam B (Hepatitis B Immune Globulin (Human) Injection), should be

administered intravenously to attain serum anti-HBs levels greater than 500 mIU/mL as described below (8, 9).

These dosing recommendations are based on a systematic review of the clinical trial literature and meta-analysis (see **PART II: SCIENTIFIC INFORMATION, CLINICAL TRIALS**). This report found that Hepatitis B Immune Globulin (HBIG) prophylaxis was most effective when administered in high doses to achieve anti-HBs levels of greater than 500 mIU/mL over longer time periods (greater than six months). The recommended dosing schedule described below is designed to achieve anti-HBs levels of greater than 500 mIU/mL. This regimen is based on that published in Terrault et al. (24) and reviewed by Shouval & Samuel (25). This regimen is currently being evaluated in a Phase III clinical trial. Recommendations for dose adjustments are based on McGory et al. (26), using a similar dosing regimen.

#### *Recommended Dose and Dosage Adjustment*

Each dose of HepaGam B should be administered as an intravenous dose of 35 mL (10,920 IU anti-HBs). The first dose should be administered concurrently with the grafting of the transplanted liver (the anhepatic phase) with subsequent dosing as recommended in Table 4. Anti-HBs levels should be measured after the first week of treatment to allow for initial adjustment of dosage.

**Table 4 HepaGam B Dosing Regimen**

Anhepatic Phase*	Week 1 Post-operative <sup>a</sup>	Months 1-3 Post-operative	Month 4 Onwards
First dose	Daily from Day 1–7	Biweekly from Day 14	Monthly

<sup>a</sup> Anti-HBs levels should be measured after the first week of treatment, to allow for initial adjustment of dosage.

HepaGam B dose adjustments may be required in patients who fail to reach anti-HBs levels of 500 mIU/mL within the first week post-liver transplantation. Patients who have surgical bleeding or abdominal fluid drainage (>500 mL) or patients who undergo plasmapheresis are particularly susceptible to extensive loss of circulated anti-HBs. The following dose adjustment is recommended:

- the dosing regimen should be increased to 5460 IU (17.5 mL intravenous) every six hours until the target anti-HBs is reached (26).

Regular monitoring of serum HBsAg, HBV-DNA and HBeAg as well as anti-HBs antibody levels should be performed to decide on the continuation of HepaGam B treatment and/or treatment adjustment.

In patients who develop treatment-related adverse events, especially during early the post-operative period when immune complexes may develop from the large amounts of hepatitis B immune globulin immunoprecipitating with HBsAg, the HepaGam B infusion rate should be decreased. Symptoms related to immune complex formation should be treated with antihistamines or analgesic agents.



### Missed Dose

If a scheduled dose is missed, HepaGam B should be administered as soon as possible after the missed dose(s). Scheduling of subsequent doses should be determined by the treating physician and the HepaGam B dosing regimen (see **Recommended Dose and Dosage Adjustment**).

### Administration

HepaGam B should be prepared for IV administration under aseptic conditions. **DO NOT SHAKE VIAL; AVOID FOAMING.** Parenteral drugs should be visually assessed for particulate matter and discoloration prior to administration.

- HepaGam B should be administered as provided through a separate intravenous line using an administration set containing an in-line filter and a constant infusion pump.
- Use normal saline as the diluent if dilution of HepaGam B is preferred prior to intravenous administration.
- Do not use dextrose (5%) in water (D5W).
- Rate of administration should be set at 2 mL per minute.
- The rate of infusion should be decreased to 1 mL per minute or slower if the patient develops discomfort or there is concern about the speed of infusion.

### **OVERDOSAGE**

Consequences of an overdose are not known.

### **ACTION AND CLINICAL PHARMACOLOGY**

#### **Mechanism of Action**

##### Post-exposure Prophylaxis

Clinical studies conducted prior to 1983 with hepatitis B immune globulins similar to HepaGam B demonstrated the advantage of simultaneous administration of hepatitis B vaccine and Hepatitis B Immune Globulin (Human) by the intramuscular route. The Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP) advises that the combination prophylaxis be provided following certain instances of hepatitis B exposure (6, 7). Recommendations on post-exposure prophylaxis are based on available efficacy data, primarily from studies in neonates (6, 7). Cases of hepatitis B are rarely seen following exposure to HBV in persons with pre-existing anti-HBs antibodies.

#### **NOC/c**

##### Prevention of Hepatitis B Recurrence following Liver Transplantation

Hepatitis B virus re-infection is the consequence of an immediate re-infection of the graft due to circulating HBV particles, a re-infection of the graft from HBV particles coming from extra hepatic sites, or both.

The mechanism whereby Hepatitis B Immune Globulin (HBIG) protects the transplanted liver against HBV re-infection is not well understood. One hypothesis is that HBIG protects naive

hepatocytes against HBV release from extra hepatic sites through blockage of a putative HBV receptor (25). Alternatively, HBIG may neutralize circulating virions through immune precipitation and immune complex formation or trigger an antibody-dependent cell-mediated cytotoxicity response resulting in target cell lysis (25). In addition, HBIG has been reported to bind to hepatocytes and interact with HBsAg within cells (27).

Regardless of the mechanism, there is evidence of a dose-dependent response to HBIG treatment (8, 9, 28).

**NOC/c**      **Pharmacodynamics**

Hepatitis B immune globulin products provide passive immunization to the hepatitis B virus and significantly decrease hepatitis B recurrence and increase graft and patient survival following liver transplantation in hepatitis B surface antigen (HBsAg) positive patients (8, 24, 29).

The clinical effectiveness of HBIG prophylaxis in the prevention of hepatitis B recurrence following liver transplantation is dependent on the dose, length of administration and the viral replication status of the patient at the time of transplant (8, 24, 29).

HBIG is most effective when administered in high doses to achieve anti-HBs levels greater than 500 mIU/mL over long time periods (greater than six months) (5). A meta-analysis of the literature data showed that patients treated with long-term high-dose HBIG had a hepatitis B recurrence rate of 15.2%, compared to a 40.4% recurrence rate in subjects treated with long-term, low-dose HBIG (9). Short-term immunoprophylaxis with HBIG may delay hepatitis B recurrence, but the overall rate of re-infection is similar to untreated patients (25). Therefore, it is important that treatment be continued long-term.

The absence of viral replication (absence of HBeAg and/or HBV DNA in serum) at the time of liver transplant is associated with an increase in the effectiveness of HBIG (see **PART II: SCIENTIFIC INFORMATION**, Table 9) (8, 9). As a result, HepaGam B is recommended in patients who have no or low levels of viral replication at the time of liver transplantation.

**NOC/c**      **Pharmacokinetics**

Currently there is no pharmacokinetic data available for HepaGam B intravenous administration in liver transplant patients. The ability of the described dosing regimen (see Table 4 in **DOSAGE AND ADMINISTRATION**) to maintain anti-HBs levels was examined in an interim analysis of 14 hepatitis B-related liver transplant patients from an ongoing clinical trial (18). Anti-HBs levels taken before and after each dose showed that the target trough of 500 mIU/mL was achieved after the first few HepaGam B doses, and maintained in the first year post-transplant in 12 of the 14 patients. As described above under **Dosing Considerations**, these levels have been associated with efficacy (24, 25).

The pharmacokinetic profile of HepaGam B in healthy volunteers after intramuscular injection of 0.06 mL/kg is summarized in Table 5.

**Table 5 Summary of HepaGam B Pharmacokinetic Parameters in Healthy Volunteers when Given via Intramuscular Injection**

	<b>C<sub>max</sub></b>	<b>T<sub>½</sub> (h)</b>	<b>AUC<sub>0-4</sub></b>	<b>Volume of Distribution</b>
<b>Single dose mean</b>	211.6 mIU/mL	24.5 days	8253.9 mIU*day/mL	7.0 ±1.5 L

### Absorption

A pharmacokinetic trial of HepaGam B (Hepatitis B Immune Globulin (Human) Injection), given intramuscularly to 30 healthy male and female volunteers demonstrated pharmacokinetic parameters similar to those reported in the literature by Scheiermann and Kuwert (30). The volume of distribution was  $7.0 \pm 1.5$  L. Maximum concentration of HepaGam B was 215.6 mIU/mL, which was reached  $5.4 \pm 2.4$  days following administration. The maximum concentration of anti-HBs achieved by HepaGam B was consistent with that of a commercially available HBIG when compared in the same comparative pharmacokinetics trial (18). There is an immediate time to the onset of HepaGam B action, and the time to steady state between intravascular and extravascular spaces is approximately five days.

### Distribution

The bioavailability of Hepatitis B Immune Globulin (Human) for intravenous use is complete and immediate (17). IgG is quickly distributed between plasma and extravascular fluid (17). Immune globulin products have been demonstrated to poorly penetrate across an intact blood brain barrier (31).

### Metabolism

Immune globulins and immune complexes are broken down in the reticuloendothelial system (17).

### Excretion

The elimination half-life of HepaGam B is 24.5 days following intramuscular administration. Based on studies with other immune globulin products (32), a slightly decreased half-life is expected following intravenous administration.

## **STORAGE AND STABILITY**

Store under refrigeration (2 to 8°C). Do not freeze. Do not use after expiration date indicated on the label.

## **SPECIAL HANDLING INSTRUCTIONS**

The product should be brought to room or body temperature before use.

The solution should be clear or slightly opalescent. Do not use solutions that are cloudy or have deposits.

## **DOSAGE FORMS, COMPOSITION AND PACKAGING**

HepaGam B (Hepatitis B Immune Globulin (Human) Injection), is a sterile solution of purified gamma globulin (5% or 50 mg/mL) fraction containing antibodies to hepatitis B surface antigen (anti-HBs).

### **Composition**

HepaGam B contains no preservative and is stabilized with 10% maltose and 0.03% polysorbate 80. Each vial is intended for single use only.

#### **Ingredients:**

- Human plasma protein ( $\geq 96\%$  Human IgG)
- Maltose
- Polysorbate 80
- May contain trace amounts of tri-n-butyl phosphate and Triton X-100<sup>®</sup>

### **Packaging**

HepaGam B, Hepatitis B Immune Globulin (Human), is supplied as:

A carton containing a **1 mL** single dose ( $>312$  IU/mL) in a 3 mL glass vial with a plastic flip off seal and a package insert

A carton containing a **5 mL** single dose ( $>312$  IU/mL) in a 6 mL glass vial with a plastic flip off seal and a package insert


## PART II: SCIENTIFIC INFORMATION

HepaGam B, indicated for the prevention of hepatitis B recurrence following liver transplantation, has been issued marketing authorization with conditions pending the results of studies to verify its clinical benefit. Patients should be advised of the nature of the authorization.

### PHARMACEUTICAL INFORMATION

#### Drug Substance

<b>Proper name:</b>	Hepatitis B Immune Globulin (Human)
<b>Chemical name:</b>	Hepatitis B Immune Globulin (Human)
<b>Molecular formula and molecular mass:</b>	Glycoprotein of approximately 160,000 Da
<b>Structural formula:</b>	Gamma Globulin (IgG)



Structure of an IgG molecules. Each chain is made up of a series of homology units of approximately 110 amino acids. The sites of proteolytic cleavage usually lie between the homology units. Membrane forms possess a hydrophobic C-terminal extension, but are otherwise identical in sequence to the secretory forms.

#### **Physicochemical properties:**

IgG is a monomeric protein with a sedimentation coefficient of 7S and a molecular weight ranging from 146,000 to 170,000 Da. Carbohydrate content of IgG is approximately 2 to 3%.

## **Product Characteristics**

HepaGam B (Hepatitis B Immune Globulin (Human) Injection) is a sterile solution of purified gamma globulin (5% or 50 mg/mL) fraction containing polyclonal antibodies to hepatitis B surface antigen (anti-HBs). It is prepared from plasma donated by individuals with high titres of anti-HBs. The plasma is purified by an anion-exchange column chromatography method (1, 7). The manufacturing process includes two viral inactivation/removal steps including a solvent detergent treatment step (using tri-n-butyl phosphate and Triton X-100<sup>®</sup>) and a Planova<sup>®</sup> 20 nm virus filtration (see **Viral Inactivation**) (3, 4, 5).

The product potency is expressed in international units (IU) by comparison to the World Health Organization (WHO) international Hepatitis B Immune Globulin reference preparation. Each vial contains greater than 312 IU/mL.

## **Viral Inactivation**

Anti-HBs plasma is collected from donors at US FDA-licensed collection facilities. Plasma donors are carefully screened for eligibility by physical exam and through questionnaires and interviews to assess risk of exposure to certain viruses. Each plasma donation is tested for HIV-1/2 and HCV antibodies and HBsAg. PCR tests for enveloped (HCV, HIV-1 and HBV) and non-enveloped (HAV and Parvovirus B-19) viruses are also performed on plasma mini-pools representing each of the individual donations used in HepaGam B manufacturing. As an additional precaution, the manufacturing plasma pools are also tested for the presence of hepatitis B (HBsAg).

To further increase product safety by reducing the risk of virus transmission, two virus removal and inactivation steps are included in the HepaGam B manufacturing process. The solvent detergent treatment step (using tri-n-butyl phosphate and Triton X-100<sup>®</sup>) inactivates lipid enveloped viruses such as hepatitis C and HIV by irreversibly destroying the lipid coat (3, 4). The Planova<sup>®</sup> 20 nm virus filter removes both lipid-enveloped and non-enveloped viruses based on virus size (4, 5). These two processes are designed to increase product safety by effectively clearing several viruses including human immunodeficiency virus (HIV), herpes viruses, hepatitis B (HBV) and hepatitis C (HCV) and reducing the risk of viral transmission. The inactivation and reduction of known enveloped and non-enveloped model viruses was validated in laboratory studies as summarized in Table 6.

**Table 6 Virus Reduction Values Obtained Through Validation Studies (4)**

	Enveloped			Non-Enveloped			
Genome	RNA		DNA	RNA		DNA	
Virus	HIV-1	BVDV	PRV	HAV	EMC	MMV	PPV
Family	Retro	Flavi	Herpes	Picorna		Parvo	
Size (nm)	80–100	50–70	120–200	25–30	30	20–25	18–24
Anion-Exchange Chromatography (Partitioning)	Not Evaluated			2.3	NE	3.4	NE
20N Filtration (Size Exclusion)	≥4.7	≥3.5	≥5.6 <sup>a</sup>	NE	4.4	NE	3.5 <sup>b</sup>
Solvent/Detergent	>4.7	≥7.1	≥5.4	Not Evaluated			
Total Reduction (log <sub>10</sub> )	≥9.4	≥10.6	≥11.0	2.3	4.4	3.4	3.5

**Abbreviations:**

HIV-1: human immunodeficiency virus-1; relevant virus for human immunodeficiency virus-1 and model for HIV-2

BVDV: bovine viral diarrhea virus; model virus for hepatitis C virus (HCV) and West Nile virus (WNV)

PRV: pseudorabies virus; model for large enveloped DNA viruses, including herpes

HAV: human hepatitis A virus; relevant virus for HAV and model for small non-enveloped viruses in general

EMC: encephalomyocarditis virus; model for HAV and for small non-enveloped viruses in general

MMV: murine minute virus; model for human B19 parvovirus and for small non-enveloped viruses in general

PPV: porcine parvovirus; model for human B19 parvovirus and for small non-enveloped viruses in general

NE.: not evaluated

<sup>a</sup> The PRV was retained by the 0.1µm pre-filter during the virus validation. Since manufacturing employs a 0.1µm pre-filter before the 20N filter, the claim of ≥ 5.6 reduction is considered applicable.

<sup>b</sup> One of the five PPV runs for the 20N filter yielded a 1.25 log clearance over the 0.1 µm pre-filter. Since production employs a 0.1 µm pre-filter before the 20N filter, the 1.25 logs were added to the 2.2 log clearance obtained over the 20N filter, and the value of 3.5 was used for determination of the mean reduction factor.

**CLINICAL TRIALS****Clinical Trials in Post-exposure Populations**

In a clinical study, the efficacy and safety of HepaGam B were evaluated in post-exposure prophylaxis in two different populations: infants born to HBsAg-positive mothers (vertical arm) and adults possibly exposed to HBV (horizontal arm). A summary of patient demographic information for this study is presented in Table 7.

**Table 7 Summary of Patient Demographics for Post-exposure Prophylaxis Study**

Study Number	Design	Dosage, Route of Administration, Duration	Study Subjects	Gender	Age
HB-004	phase 3, multi-centre, open-label, non-randomized, historically controlled study	0.5 mL intramuscular administered once, within 12 hours of birth	253 infants born to HBsAg-positive mothers; 178 in efficacy analysis population	M: 137 (54.2%); F: 116 (45.8%)	less than 12 hours
		0.06 mL/kg intramuscular once, within 48 hours of exposure to hepatitis B virus	42 adults dosed, 23 completed the study	M: 17 (40.5%) F: 25 (59.5%)	37.8 (10.3) yr; range 20.5–57.4

Infants and adults in study HB-004 also received the hepatitis B vaccine on Day 0, concurrent with HepaGam B, and on Days 30 and 180, as per the manufacturer’s recommendation. All infants were followed up for safety for up to one year and adults for six months following HepaGam B administration.

**Table 8 Protection Rate against Hepatitis B Infection in Infants Born to HBsAg-positive Mothers, who were Administered HepaGam B within 12 Hours of Birth and Hepatitis B Vaccine**

N	Protection Rate	95% Confidence Interval
178	0.978	(0.944, 0.994)

Exact confidence interval limits for the binomial proportion using the *F* distribution method

Since four infants tested positive for HBsAg during the study, a 0.98 (174/178) protection rate was achieved (Table 8). HepaGam B was not inferior to the historical reference protection rate of 0.97 (lower 95% confidence bound for the calculated protection rate was greater than 0.92). Of note, each of the four infants who became HBsAg positive during the study subsequently became HBsAg-negative. Two of them seroconverted and became anti-HBs positive during the study. The other two infants remained anti-HBs negative (anti-HBs <10 mIU/mL) after one year follow-up. Anti-HBc (IgM), indicating a new HBV infection, was detected in one of these four infants.

A total of 42 adults received HepaGam B and hepatitis B vaccine. Among them, 23 completed the study. None of the 23 adults became HBsAg positive during the study. The efficacy results from the remaining 19 adults are unknown.

Thus, HepaGam B is effective in combination with the hepatitis B vaccine in post-exposure prophylaxis against hepatitis B infection.

## **NOC/c**

### **Clinical Trials in Liver Transplant Patients**

A Phase III clinical trial for HepaGam B (Hepatitis B Immune Globulin (Human) Injection) in liver transplant patients is ongoing. Interim efficacy results are available from the first 16 patients completing this study.



In addition, a systematic review of the clinical trial literature and meta-analysis, supporting the efficacy of Hepatitis B Immune Globulin (HBIG) prophylaxis in the prevention of hepatitis B recurrence following liver transplantation was completed. A summary of the review is presented below.

### A Systematic Review of the Clinical Trial Literature and Meta-Analysis

A large number of literature reports have shown that treatment with Hepatitis B Immune Globulin, or HBIG, has been effective in decreasing hepatitis B recurrence and increasing graft and patient survival following liver transplantation in HBsAg positive patients (8, 24, 29). In particular, a landmark European study examining 372 consecutive HBsAg-positive patients from 17 centres established the efficacy of long-term immunoprophylaxis with high-dose HBIG in the prevention of hepatitis B recurrence after liver transplantation and changed the clinical practice for this indication (28). A systematic review and meta-analysis of this literature data was conducted to assess the efficacy of HBIG in the prevention of HBV recurrence following liver transplantation (9).

The meta-analysis examined clinical literature reports from studies of HBIG monotherapy and/or no prophylaxis following liver transplantation in subjects with hepatitis B. A total of 37 studies in 1922 patients were analyzed. The main finding was that HBIG prophylaxis is effective in the prevention of HBV recurrence following liver transplantation as compared to no prophylaxis. The meta-analysis results indicated that HBIG prophylaxis significantly decreases hepatitis B recurrence following liver transplantation, with hepatitis B recurrence rates of 37.5% in patients receiving HBIG compared to 80.3% for patients receiving no prophylaxis (14). The meta-analysis also showed a correlation between the reduced hepatitis B recurrence rate in patients treated with HBIG and a decreased incidence of hepatitis B virus (HBV)-related deaths following liver transplantation: from 14% in patients receiving no prophylaxis to 5% in patients treated with HBIG (9).

HBIG prophylaxis was most effective when administered in high doses to achieve anti-HBs concentrations greater than 500 mIU/mL over long time periods (greater than six months) to patients that had no or low levels of HBV replication immediately prior to liver transplantation (9). These results are demonstrated in Table 9.

**Table 9 Results from a Meta-analysis of Literature Data Showing Efficacy of Long-term High-dose HBIG**

<b>Treatment Group</b>	<b>HBV Recurrence Rate % (n)</b>
No prophylaxis	80.3% (n=362)
HBIG prophylaxis (all durations and doses)	37.5 % (n=1496)
Short-term HBIG	72.7 % (n=166)
Long-term HBIG	23.0% (n=1028)
Long-term Low- dose HBIG	40.4% (n=289)
Long-term High- dose HBIG	15.2 % (n=254)
Long-term High-dose Replicators	49.6% (n=27)
Long-term High-dose Non-replicators	5.4% (n=175)

Short-term <6 months treatment

Long-term  $\geq 6$  months treatment

Low-dose = anti-HBs targets 100–200 IU/L

High-dose = anti-HBs targets  $\geq 500$  IU/L

Replicators = HBV-DNA positive or HBeAg positive at the time of transplantation

Non-replicators = HBV-DNA negative and HBeAg negative at the time of transplant

### Clinical Trials for the Prevention of Hepatitis B Recurrence Following Liver Transplantation

A clinical trial examining the effectiveness of HepaGam B in the prevention of hepatitis B recurrence following liver transplantation is currently ongoing with more than 25 patients enrolled. The study is a multi-center, open-labeled, superiority study involving HBsAg-positive/HBeAg-negative liver transplant patients. The study included two arms; an active treatment group of patients enrolled to receive the described dosing regimen of HepaGam B starting during transplant and continuing over the course of a year, and a retrospective untreated control group of historical patients with data gathered by chart review. An interim report of this study evaluated the efficacy of HepaGam B in preventing HBV recurrence compared to retrospective untreated control patients.

**Table 10 Summary of Patient Demographics for Clinical Trials in Hepatitis B-related Liver Transplant Patients**

Study No.	Trial Design	Dosage, Route of Administration and Duration	Study Subjects (n=number)	Mean Age (Range)	Gender
HB-005 (Interim analysis)	Multi-center, open-labeled, historically controlled, superiority study in HBsAg-positive/HBeAg-negative liver transplant patients	HepaGam B was administered by intravenous infusion of $>10\,000$ IU/dose. The dosing regimen consisted of 24 doses over a 1-year period, beginning during transplant, followed by daily for 7 days, biweekly for 3 months and then monthly.	n=30 (n=16 for HepaGam B and n=14 for retrospective untreated control group)	48.8 years (33–68 years)	27 Males, 3 Females

The interim analysis included data from 30 liver transplant patients; 16 HepaGam B patients who have completed the study and 14 retrospective untreated control patients. The HepaGam B active treatment group (n=16) consisted of 14 male and two female patients with a mean age of 47.5 years (range of 33 to 66 years). All active patients were Caucasian, transplanted in Turkey between April 2004 and June 2005. The retrospective untreated control group (n=14) consisted of 13 male and one female patients with a mean age of 50.2 years (range 37 to 68 years). Retrospective untreated control patients were Caucasian (n=7, 50%) or Asian (n=7, 50%), transplanted in North America between October 1988 and April 1992. The patients in both groups were HBsAg-positive/HBeAg-negative liver transplant patients who met similar entry criteria, had similar medical history and had similar status at transplant based on MELD and/or ChildPugh-Turcotte scores.

**Table 11 Interim Results of Study HB-005 for the Prevention of Hepatitis B Recurrence following Liver Transplantation**

<b>Primary Endpoint</b>	<b>HepaGam B</b>	<b>Retrospective Untreated Control</b>	<b>P-value (Fischer's Exact Test)</b>
HBV Recurrence Proportion, % (95% confidence interval)	13.3 (0.2–33.9)	85.7 (57.2–98.2)	<0.001

For the primary efficacy endpoint of the proportion of patients with HBV recurrence (HBsAg-positive after four weeks post-OLT), a significant treatment effect was observed. As summarized in Table 11, HBV recurrence was seen in 2/15 or 13% of HepaGam B patients compared to 12/14 or 86% of retrospective untreated control patients. One of the 16 HepaGam B patients died two weeks post-transplant and was excluded from all efficacy analyses but was included for safety analyses. The death was not HBV or study drug related.

The conclusion that HepaGam B monotherapy post-OLT is effective at preventing HBV recurrence post-OLT is further supported by the secondary endpoints of time to recurrence, survival, anti-HBs levels and biochemical markers of liver inflammation. Time to recurrence for the HepaGam B treatment group was 365 days for the one HBsAg-positive patient. In comparison, the retrospective untreated control patients had a median time to recurrence of 88 days with a 95% confidence interval of 47 to 125 days. Survival calculations showed that 93% (14/15) of patients in the active treatment group survived for at least one year post-OLT compared to 43% (6/14) of retrospective control patients. One active patient died 266 days post-OLT. The median time to death for the retrospective control patients was 339 days calculated using the product limit method. The endpoints for HBV recurrence were supported by an observed drop in anti-HBs levels and elevated liver function tests at the time of recurrence.

### **Comparative Bioavailability Studies**

The comparative pharmacokinetics of HepaGam B and a commercially available HBIG product following intramuscular administration was assessed in healthy male and female subjects. The study was a single-centre, randomized, single blind, comparative, parallel study. The pharmacokinetic data was assessed by measurement of plasma levels of anti-HBs over a period of 84 days (~3 half-lives of immune globulin products).

This study was conducted in 60 healthy volunteer subjects. The HepaGam B treatment group (n=30) consisted of 16 male and 14 female subjects with a mean age of 35 ±10 years (range 22 to 55 years) and a mean weight of 71.8 ±13.3 kg (range 46.5 to 93.0 kg). The comparator treatment group (n=30) consisted of 17 male and 13 female subjects with a mean age of 35 ±8 years (range 22 to 54 years) and a mean weight of 69.0 ±10.1 kg (range 51.0 to 91.0 kg).

**Table 12 Summary of Patient Demographics for Pharmacokinetics Study**

Study No.	Trial Design	Dosage, Route of Administration and Duration	Study Subjects (n=number)	Mean Age (Range)	Gender
HB-002	Single centre, randomized, single-blind, parallel arm study in healthy volunteers.	Single dose of 0.06 mL/kg by intramuscular injection	n=60 (30 in each treatment arm)	35 years (22–55 years)	33 Males, 27 Females

**Table 13 Measured Pharmacokinetic Parameters from Subjects Administered Either HepaGam B or the Reference HBIG Product at a Dose of 0.06 mL/kg Intramuscular**

Parameter	HepaGam B	Reference HBIG	% Ratio of Geometric Means	90% Confidence Interval
	Geometric Mean Arithmetic Mean (CV%)			
AUC <sub>T</sub> (mIU*day/mL)	7356.7 7521.3 (20.6)	5267.7 5418.4 (23.2)	139.7	126.3–154.5
AUC <sub>I</sub> (mIU*day/mL)	8253.9 8477.4 (22.9)	6051.5 6208.6 (22.8)	136.4	123.2–151.0
C <sub>max</sub> (mIU/mL)	211.6 215.6 (19.1)	153.5 157.2 (22.5)	137.9	125.9–151.1
T <sub>max</sub> <sup>a</sup> (days)	5.4 (43.9)	6.6 (38.9)		
T <sub>1/2</sub> <sup>a</sup> (days)	24.5 (18.9)	24.4 (21.1)		

<sup>a</sup> Expressed as the arithmetic mean (CV%) only.

When the ratios of the geometric means and the 90% confidence intervals were corrected for measured potency, the AUC and C<sub>max</sub> ratios met the standard bioequivalence criteria.

## DETAILED PHARMACOLOGY

### Animal Studies

Nonclinical pharmacology studies have not been performed with Hepatitis B Immune Globulin (Human) as there is broad experience in humans with intravenous and intramuscular administration of immune globulin products. Since the product is of human origin, immunogenicity is expected when administered to animals.

### Human Studies

A single-centre, randomized, single-blind, comparative, parallel arm study was conducted to assess the safety and comparative pharmacokinetics of HepaGam B and a reference product when administered intramuscularly to healthy male and female subjects under fasting conditions.

Seventy subjects were enrolled in the study, and 61 subjects received a single dose of 0.06 mL/kg of either HepaGam B or the reference product. Sixty subjects completed the study (thirty subjects in each treatment arm).

Safety and pharmacokinetic data as assessed by anti-HBs plasma levels of all subjects who completed the study was collected for 84 days (3 half-lives of the product).

The half-life of HepaGam B was  $24.5 \pm 4.6$  days and the volume of distribution was  $7.0 \pm 1.5$  L. Maximum concentration of HepaGam B was 215.6 mIU/mL and was reached in  $5.4 \pm 2.4$  days.

As the test:reference ratios and 90% confidence intervals for the parameters  $AUC_{0-T}$ ,  $AUC_{0-inf}$  and  $C_{max}$  (log-transformed data) met the 0.8 to 1.25 criteria, HepaGam B was concluded to be bioequivalent to the reference product.

## **TOXICOLOGY**

Toxicology studies have not been performed with Hepatitis B Immune Globulin (Human) because the product has been formulated with ingredients that are known to be non-toxic at the levels at which they are present in the final product.

## **REFERENCES**

1. Bowman JM, Friesen DA, Pollock JM, Taylor WE. WinRho: Rh immune globulin prepared by ion exchange for intravenous use. *Can Med Assoc J* 1980; 123:1121-5.
2. Friesen AD, Bowman JM, Price HW. Column Ion Exchange Preparation and Characterization of an Rh Immune Globulin (WinRho) for Intravenous Use. *J Appl Biochem* 1981; 3:164-75.
3. Horowitz B. Investigations into the application of Tri(n-Butyl)Phosphate/Detergent Mixtures to Blood Derivatives. In: Morgenthaler J, editor. *Virus Inactivation in Plasma Products*. *Curr Stud Hematol Blood Transfus*. Basel, Karger; 1989; 56:83-96.
4. Unpublished viral validation data on file.
5. Burnoff T. Value of virus filtration as a method for improving the safety of plasma products. *Vox Sang* 1996; 70:235-6.
6. CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Part 1: Immunization of infants, children, and adolescents. *MMWR* 2005; 54(RR-16):1-32.
7. CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Part 2: Immunization of adults. *MMWR* 2006; 55(RR-16):1-33.

8. Roche B, Samuel D. Liver transplantation for hepatitis B virus-replated liver disease: Indications, prevention of recurrence and results. *J Hepatol* 2003; 39:S181-9.
9. Unpublished data on file.
10. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. *Neurology* 1994; 44(2):223-6.
11. Wolberg AS, Kon RH, Monroe DM, Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. *Am J Hematol* 2000; 65(1):30-4.
12. Woodruff RK, Grigg AP, Firkin FC, Smith IL. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. *Lancet* 1986; 2(8500):217-8.
13. Zhang R, Szerlip HM. Reemergence of sucrose nephropathy: acute renal failure caused by high-dose intravenous immune globulin therapy. *South Med J* 2000; 93(9):901-4.
14. Perazella MA, Cayco AV. Acute renal failure and intravenous immune globulin: sucrose nephropathy in disguise? *Am J Ther* 1998; 5(6):399-403.
15. Hansen-Schmidt S, Silomon J, Keller F. Osmotic nephrosis due to high-dose immunoglobulin therapy containing sucrose (but not with glycine) in a patient with immunoglobulin A nephritis. *Am J Kidney Dis* 1996; 28(3):451-3.
16. Bowman, JM. Antenatal suppression of Rh alloimmunization. *Clin Obst & Gynec* 1991; 34:296-303.
17. Committee for Proprietary Medicinal Products (CPMP). Core SPC for human plasma derived hepatitis-B immunoglobulin for intravenous use (CPMP/BPWG/4027/02). London, UK: The European Agency for the Evaluation of Medicinal Products. 2003.
18. Unpublished clinical data on file.
19. Ellis EF and Henney CS. Adverse reactions following administration of human gamma globulin. *J Allerg* 1969; 43:45-54.
20. Miura M, Katada Y, Ishihara J. Time interval of measles vaccination in patients with Kawasaki disease treated with additional intravenous immune globulin. *Eur J Pediatr* 2004;163(1):25-9.
21. Ruderman JW, Barka N, Peter JB, Stiehm ER. Antibody response to MMR vaccination in children who received IVIG as neonates. *Am J Dis Child* 1991;145(4):425-6.
22. Canadian Immunization guide. Health Canada, Seventh Edition, 2006.
23. Beasley RP et al.: Efficacy of hepatitis B immune globulin for the prevention of perinatal transmission of the hepatitis B virus carrier state: Final report of a randomized double-blind, placebo-controlled trial. *Hepatology* 1983; 3:135-41.

24. Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. *Hepatology* 1996; 24(6):1327-33.
25. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. *Hepatology* 2000; 32(6):1189-95.
26. McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough CS, Dickson RC et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. *Transplantation* 1996; 61(9):1358-64.
27. Schilling R, Ijaz S, Davidoff M, Lee JY, Locarnini S, Williams R, Naoumov NV. Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. *J Virol* 2003; 77(16):8882-92.
28. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP et al. Liver transplantation in European patients with the hepatitis B surface antigen. *N Engl J Med* 1993; 329(25):1842-7.
29. Tchervenkov JI, Metrakos P, Deschenes M, Alpert E, Tector AJ, Cantarovich M et al. Decreasing viral load pretransplant and passive immunoprophylaxis with hepatitis B immunoglobulin post-transplant prevents hepatitis B virus recurrence after liver transplantation: an 8-year single-center experience. *Transplant Proc* 2001; 33(1-2):1514-5.
30. Scheiermann N, Kuwert EK. Uptake and elimination of hepatitis B immunoglobulins after intramuscular application in man. *Develop Biol Standard* 1983; 54:347-55.
31. Wurster U, Haas J. Passage of intravenous immunoglobulin and interaction with the CNS. *J Neurol Neurosurg Psychiatry* 1994; 57:21-5.
32. Smith GN, Griffiths B, Mollison D, Mollison PL. Uptake of IgG after intramuscular and subcutaneous injection. *Lancet* 1972; 1 (7762):1208-12.

## PART III: CONSUMER INFORMATION

*HepaGam B, for use in the prevention of hepatitis B recurrence following liver transplantation, has been approved with conditions, pending the results of studies to verify its clinical benefit. For more information, patients are advised to contact their health care provider.*

### What is a Notice of Compliance with Conditions (NOC/c)?

An NOC/c is a form of market approval granted to a product on the basis of **promising** evidence of clinical effectiveness following review of the submission by Health Canada.

Products approved under Health Canada's NOC/c policy are intended for the treatment, prevention or diagnosis of a serious, life-threatening or severely debilitating illness. They have demonstrated promising benefit, are of high quality and possess an acceptable safety profile based on a benefit/risk assessment. In addition, they either respond to a serious unmet medical need in Canada or have demonstrated a significant improvement in the benefit/risk profile over existing therapies. Health Canada has provided access to this product on the condition that sponsors carry out additional clinical trials to verify the anticipated benefit within an agreed upon time frame.

### HepaGam B®

Hepatitis B Immune Globulin (Human) Injection

This leaflet is part III of a three-part "Product Monograph" published when HepaGam B was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about HepaGam B. Contact your doctor or pharmacist if you have any questions about the drug.

### ABOUT THIS MEDICATION

What the medication is used for:

- Prevention of hepatitis B infection following exposure to the hepatitis B virus (post-exposure prophylaxis)
- Prevention of hepatitis B recurrence following liver transplantation in patients with hepatitis B.

What it does:

HepaGam B binds to the hepatitis B virus and helps to remove the virus from circulation.

HepaGam B also prevents development of a hepatitis B infection after exposure to the hepatitis B virus. HepaGam B should be administered within 12 hours of birth or 48 hours of exposure to the hepatitis B virus.

HepaGam B protects the newly transplanted liver from re-infection with the hepatitis B virus. For HepaGam B to be effective in preventing hepatitis B recurrence, treatment should be started during liver transplantation and continued regularly after transplant. Laboratory tests will determine if HepaGam B is working by measuring levels of HepaGam B in serum (the liquid portion of blood) and by looking for signs of hepatitis B infection.

When it should not be used:

- in patients with a history of allergic reactions to blood products
- in patients deficient in IgA, a specific type of blood protein

What the medicinal ingredient is:

Hepatitis B Immune Globulin (Human)

What the important non-medicinal ingredients are:

Human plasma protein  
Maltose  
Polysorbate 80

HepaGam B may contain trace amounts of tri-n-butyl phosphate and Triton X-100®.

*For a full listing of non-medicinal ingredients see Part 1 of the product monograph.*

What dosage forms it comes in:

HepaGam B is a sterile liquid supplied in 1 mL and 5 mL vials containing >312 IU/mL.

## WARNINGS AND PRECAUTIONS

### Serious Warnings and Precautions

- **HepaGam B is made from human plasma which may contain the causative agents of viral diseases. The risk of getting a disease from this product has been reduced by screening plasma donors, testing for the presence of certain viruses and by inactivating and removing certain viruses during manufacturing. However, there is still a possibility that plasma products could transmit disease.**
- **Allergic or anaphylactic reactions are rare. These reactions can occur in patients with a history of allergy to blood products or in patients lacking the IgA blood protein.**
- **Before using HepaGam B, discuss the risk and benefits with your doctor.**

BEFORE you use HepaGam B talk to your doctor or pharmacist if:

- You have experienced allergic reactions to blood products in the past
- You have a known IgA deficiency
- You are pregnant or nursing
- If you use any device to measure blood or urine glucose

While being treated with HepaGam B, regular blood tests will be conducted to check for adequate drug levels.

### INTERACTIONS WITH THIS MEDICATION

Drugs that may interact with HepaGam B have not been established.

Immune globulins like HepaGam B may impair the effectiveness of certain live virus vaccines such as measles, rubella (German



measles), mumps and varicella (chicken pox). Talk to your doctor if you have been recently vaccinated.

**PROPER USE OF THIS MEDICATION**

Usual dose (post-exposure prophylaxis):

Each neonatal dose of HepaGam B is 0.5 mL, administered once intramuscularly. An adult dose of HepaGam B is 0.06 mL/kg, administered once intramuscularly.

Usual dose (following liver transplant):

Each dose of 35 mL (10,920 international units) HepaGam B will be given by an intravenous injection taking approximately 20 minutes.

The typical dose schedule is as follows:

- first dose during liver transplantation operation
- daily doses for the first week post-operative
- once every two weeks for the first three months post-operative
- once a month thereafter

Overdose:

The consequences of an overdose are not known. In case of an overdose, consult your doctor.

Missed Dose:

If a scheduled dose is missed, it should be given as soon as possible after the missed dose. Your doctor will adjust your dosing schedule if required.

**SIDE EFFECTS AND WHAT TO DO ABOUT THEM**

The most common side effects are chills, fever, headaches, vomiting, allergic reactions, nausea, arthralgia (pain in joints) and moderate low back pain. These side effects are usually mild, but if they require treatment ask your health care professional.

**SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM**

Symptom / effect		Talk to your doctor or pharmacist		Stop taking drug and call your doctor or pharmacist
		Only if severe	In all cases	
Common	Not applicable*			
Uncommon	Allergic Reaction		✓	✓

\* Serious side effects are not common.

*This is not a complete list of side effects. For any unexpected effects while taking HepaGam B, contact your doctor or pharmacist.*

**HOW TO STORE IT**

Store HepaGam B under refrigeration. Do not freeze. Do not use after expiration date.

Keep out of reach of children.

**REPORTING SUSPECTED SIDE EFFECTS**

To monitor drug safety, Health Canada collects information on serious and unexpected effects of drugs. If you suspect you have had a serious or unexpected reaction to this drug you may notify Health Canada by:

Toll-free telephone: 866-234-2345

Toll-free fax: 866-678-6789

By email: [cadtmp@hc-sc.gc.ca](mailto:cadtmp@hc-sc.gc.ca)

By regular mail:

National AR Centre  
 Marketed Health Products Safety and Effectiveness  
 Information Division  
 Marketed Health Products Directorate  
 Tunney's Pasture, AL 0701C  
 Ottawa ON K1A 0K9

*NOTE: Before contacting Health Canada, you should contact your physician or pharmacist.*

**MORE INFORMATION**

This document plus the full product monograph, prepared for health professionals can be obtained by contacting Saol Therapeutics Research Limited at 1-877-443-0224.

This leaflet was prepared by Saol Therapeutics Research Limited.

HepaGam B® is a registered trademark of Saol.

PLANOVA® is a registered trademark of Asahi Kasei Medical Co., Ltd. TRITON® is a registered trademark of Union Carbide Corporation.

Last revised: November 14, 2017